Emerging Biopharma Program

US Emerging Biopharma and Medical Device Sponsors

Jeeva launched an innovative program on Aug. 1, 2023, to support early phase innovation in the “US Emerging Biopharma and medical device industry,” struggling to cope with the short-term effects of the Inflation Reduction Act 2022.
US Emerging biopharma and medical device sponsors - Emerging Biopharma
Check our Latest PR - Emerging Biopharma

Check our latest PR for Emerging Biopharma

The Inflation Reduction Act: How Price Controls Could Disrupt Clinical Trials and Stifle Medical InnovationThe Inflation Reduction Act of 2022 has introduced drug pricing controls that may initially benefit patients. However, these controls could have unintended consequences on drug development and investment eventually. To mitigate these pressures, there is an opportunity to modernize clinical trials. Dr. Harsha Rajasimha, CEO of Jeeva Trials, plans to help biopharmaceutical and medical device sponsors reduce the costs of early phase clinical trials and overcome these challenges.

Benefits to the Emerging Biopharma

We Interviewed Hundreds Of Patients, Advocates, And Foundation Leaders - Patient Groups

Compliance Programs Supported

Client Testimonials

Ready to Explore Jeeva eClinical Cloud for Your Study?

Jeeva eClinical Cloud has a user-friendly and intuitive interface. The platform is designed to be easy to navigate and operate, even for users who may not have extensive technical expertise. This means you can focus on conducting your study rather than getting bogged down by complex software systems.